New hope for stomach cancer: triple therapy trial launches
Disease control
Not yet recruiting
This phase 3 trial tests whether adding TST001 (a drug targeting a protein found on stomach cancer cells) to standard chemotherapy and immunotherapy can help people with advanced stomach or gastroesophageal junction cancer live longer without their disease getting worse. About 82…
Phase: PHASE3 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 02:16 UTC